Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey.
about
The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with DiabetesA new health technology: where is the consensus on a clinically worthwhile benefit?When people would choose treatment has wide implications.Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis.Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study.Evaluation of large scale clinical trials and their application to usual practiceIs population coronary heart disease risk screening justified? A discussion of the National Service Framework for coronary heart disease (Standard 4)Prevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis.Cardiology.Patients' expectations of screening and preventive treatments.How do patients' treatment preferences compare with those of clinicians?Economic inequalities in burden of illness, diagnosis and treatment of five long-term conditions in England: panel study.A systematic review of postcoital bleeding and risk of cervical cancerPredictors of patients' preferences for treatments to prevent heart disease.What benefit do patients expect from adding second and third antihypertensive drugs?Factors involved in deciding to start preventive treatment: qualitative study of clinicians' and lay people's attitudesMultidisciplinary team decision-making in cancer and the absent patient: a qualitative studyDoes self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials.Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists.Care and Do Not Harm: Possible Misunderstandings With Quaternary Prevention (P4) Comment on "Quaternary Prevention, an Answer of Family Doctors to Over Medicalization".Patients' preferences shed light on the murky world of guideline-based medicine.Engaging patients in medical decision making.Clinicians' preferences for treatments to prevent coronary heart disease: a postal survey.Understanding the concept of medical risk reduction: a comparison between the UK and Germany.Patients' acceptance of antihypertensive therapy to prevent cardiovascular disease: a comparison between South Asians and Caucasians in the United Kingdom.Introduction of photodynamic therapy for the treatment of neovascular age-related macular degeneration: tracking a moving target.Coronary heart disease: causes and drug treatment--spouses' conceptions.Willingness to take drugs to prevent serious chronic diseases.Using a problem detection study (PDS) to identify and compare health care provider and consumer views of antihypertensive therapy.How Good is Our Best Guess? Clinical Application of the WHO FRAX Tool in Osteoporotic Fracture Risk Determination and Treatment Decisions.Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.
P2860
Q28550096-D33025BE-0730-4D3B-867D-FE3E3A9EC2B6Q31095117-0653D9D7-B261-4565-A4DF-D56B164F9593Q33802473-C6AABC3B-8E53-47C2-9122-62012421879CQ33941781-F2B26C5B-BECC-4AB1-B763-953506057095Q33942503-C295E08B-32A9-4036-A5B5-9E23B4889DA1Q34085318-586F915F-8EAA-4A11-A7CF-28CE768120BFQ34220900-CE8408B4-DA0A-4118-A756-1EF0F586939CQ34237514-09A24E76-3F47-4383-97FE-1436C99E2686Q34249451-5880AEBF-80BA-444D-AF4B-B5E8A52C4AF6Q34311491-1B825820-8A5C-4798-8EF5-BA64E817C41EQ34354202-5531920E-5F77-4ED1-8DAF-128958639791Q34417180-0ADE0733-D772-4D9B-BFA8-CE258905D948Q35724011-F8A2A384-1FD6-4FBA-96E2-CC99EFF159E2Q35772634-B13A0554-8AF3-4F3D-8090-D3D6A9365BDBQ35804337-23C7F541-8B92-4C60-B96E-FA1F0AF38413Q36275050-7B41952D-9DB5-4EC7-8F44-639553759263Q37133952-93EF4134-86CD-46EE-93B7-B99B4C580C26Q37760953-EB766912-01B5-4C81-AA40-D8B33C76B3EEQ40269632-6652DE7C-A3A1-4924-8004-6E2A7A2C7102Q42426587-AC463645-2D84-4CDD-9E0D-7935B99E1B56Q42611552-16ACCF02-38C5-476C-9D30-AFF76A0195C1Q42773763-3DFE01BB-E2F6-49AA-BD18-54438E51936FQ43012845-86281893-FA2A-440B-9BC6-6705E58B3F6EQ46701346-AD13AF2B-B49D-4F3A-B5E5-0EB8BCDAB328Q47568445-E7640BAD-3286-4DFB-AD7C-CAC4D6494573Q47766099-E7135DFD-09DF-4972-AD4E-23CAC6B71738Q48563840-A0282FCB-2742-4609-B7B0-78811775F7B0Q50802718-F28C06E7-6F4F-471E-8BF8-A7C2C7E57C2FQ52105075-466DD541-05F6-4681-A34A-307760F2278AQ53776133-26589CD0-E79E-4ED5-B1B9-760B47E37DF7Q55428965-EFA430BD-CA3F-40B8-BB18-C55D32DD6E4C
P2860
Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thresholds for taking antihype ...... groups: questionnaire survey.
@en
Thresholds for taking antihype ...... groups: questionnaire survey.
@nl
type
label
Thresholds for taking antihype ...... groups: questionnaire survey.
@en
Thresholds for taking antihype ...... groups: questionnaire survey.
@nl
prefLabel
Thresholds for taking antihype ...... groups: questionnaire survey.
@en
Thresholds for taking antihype ...... groups: questionnaire survey.
@nl
P2860
P1433
P1476
Thresholds for taking antihype ...... groups: questionnaire survey.
@en
P2093
P2860
P304
P356
10.1136/BMJ.320.7247.1446
P407
P577
2000-05-01T00:00:00Z